arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Scholar Rock Holding Corp

SRRK
$45.48 ▼ -0.62 (-1.33%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
10 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

Scholar Rock Holding Corp faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.2B
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -88.0% ↘
FCF / Share $-2.62 ↘
Trailing P/E —
Price / Book 20.1x
FCF Yield —
Debt / Equity 0.41
info Valuation on last close. End-of-day price, Nov 5, 2026.

10-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0% —
Net Income Profit after all expenses
$-377.94M
↓ -53.5% —
Operating Margin Operating profit as % of sales
-404.8%
↓ -52.1% —
FCF / Share Free cash flow per share
$-2.62
↓ -30.2% —
Long-Term Debt Long-term obligations
$99.71M
↑ +98.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
4
Financial Health ↑
36
Cash Quality ↓
53

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 10 years · 38 quarters